Coherus has divested its UDENYCA biosimilar franchise and transformed into a pure-play immuno-oncology company focused solely on LOQTORZI and its pipeline candidates.
The company has fundamentally restructured its business model by selling off UDENYCA, which was a key revenue-generating biosimilar product launched in 2019. This strategic pivot concentrates the company entirely on cancer immunotherapy, reducing diversification but potentially allowing more focused investment in their PD-1 inhibitor platform. The transformation carries execution risk as the company now depends heavily on LOQTORZI's commercial success and pipeline advancement.
The financial statements reflect the major asset divestiture, with inventory declining dramatically and total assets shrinking by over 40% to $258.3M. Total liabilities decreased substantially to $197.3M, and interest expense was meaningfully reduced to $9.0M, suggesting debt paydown from divestiture proceeds. However, operating losses expanded notably, and while SG&A expenses decreased by 40%, the overall financial profile shows a smaller, more focused but currently unprofitable entity.
Inventory drawn down 95.5% — strong sell-through or deliberate destocking; watch for supply constraints.
Capex reduced 86% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Liabilities reduced 66% — deleveraging improves balance sheet strength and financial flexibility.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities reduced — improved short-term financial position and working capital health.
Total assets contracted 42.4% — asset sales, write-downs, or balance sheet optimization underway.
SG&A reduced 40% — improved cost efficiency or headcount reduction improving operating margins.
Current assets declined 39.5% — monitor working capital adequacy and short-term liquidity.
Cash decreased 29.5% — monitor burn rate and upcoming capital needs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →